Published in Bioorg Med Chem on July 22, 2010
Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90. Bioorg Med Chem Lett (2011) 1.01
Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulations. PLoS Comput Biol (2012) 1.01
The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis. J Mol Biol (2015) 0.98
Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chem Biol (2011) 0.93
Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds. Tetrahedron (2012) 0.91
A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorg Med Chem Lett (2013) 0.83
High-throughput screen of natural product libraries for hsp90 inhibitors. Biology (Basel) (2014) 0.81
Response surface methodology in docking study of small molecule BACE-1 inhibitors. J Mol Model (2012) 0.80
An Hsp90 modulator that exhibits a unique mechanistic profile. Bioorg Med Chem Lett (2012) 0.80
Natural iminosugar (+)-lentiginosine inhibits ATPase and chaperone activity of hsp90. PLoS One (2012) 0.78
Chemically accessible hsp90 inhibitor that does not induce a heat shock response. ACS Med Chem Lett (2014) 0.76
Consecutive isocyanide-based multicomponent reactions: synthesis of cyclic pentadepsipeptoids. Beilstein J Org Chem (2014) 0.76
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix. Bioorg Med Chem (2014) 0.76
Effectively delivering a unique hsp90 inhibitor using star polymers. ACS Med Chem Lett (2013) 0.75
Biscogniauxone, a New Isopyrrolonaphthoquinone Compound from the Fungus Biscogniauxia mediterranea Isolated from Deep-Sea Sediments. Mar Drugs (2016) 0.75
First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90. Sci Rep (2015) 0.75
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A (1994) 6.74
Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature (2006) 5.42
Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst (2000) 4.54
Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics (2006) 4.44
Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med (2002) 3.53
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem (2000) 3.06
17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther (2003) 2.74
Heat shock protein 90. Curr Opin Oncol (2003) 2.73
Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci (2002) 1.97
Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics (2008) 1.94
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets (2003) 1.80
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol (2005) 1.80
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A (2006) 1.78
Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett (2006) 1.70
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol (2005) 1.60
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep (2004) 1.46
Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol (2003) 1.40
HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A (2008) 1.39
Mechanism of dimer formation of the 90-kDa heat-shock protein. Eur J Biochem (1995) 1.38
17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res (2006) 1.36
Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Proc Natl Acad Sci U S A (2006) 1.31
Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors. J Med Chem (2004) 1.31
Synthesis of second-generation sansalvamide A derivatives: novel templates as potential antitumor agents. J Org Chem (2007) 1.26
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res (2004) 1.23
NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. Chembiochem (2003) 1.20
N-methylsansalvamide a peptide analogues. Potent new antitumor agents. J Med Chem (2005) 1.19
Colorectal cancer prevention and treatment. Gastroenterology (2000) 1.19
Heat shock proteins in human cancer. Electrophoresis (2000) 1.18
Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem (2008) 1.17
Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines. J Med Chem (2008) 1.17
Monomer arrangement in HSP90 dimer as determined by decoration with N and C-terminal region specific antibodies. J Mol Biol (1999) 1.14
The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem (2006) 1.13
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol (2005) 1.11
Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett (2005) 1.09
ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res (2005) 1.07
A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorg Med Chem (2009) 1.04
Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. ACS Med Chem Lett (2010) 1.02
Peptides as drugs: is there a market? J Pept Sci (2002) 1.02
N-Methylsansalvamide, a cytotoxic cyclic depsipeptide from a marine fungus of the genus fusarium. Phytochemistry (2000) 1.01
N-methylated cyclic pentaalanine peptides as template structures. J Am Chem Soc (2006) 1.01
Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem Rev (2005) 0.99
Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells. J Cell Biochem (2006) 0.99
Synthesis of Sansalvamide A derivatives and their cytotoxicity in the MSS colon cancer cell line HT-29. Bioorg Med Chem (2006) 0.97
A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Commun (2006) 0.96
Mechanism of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A. Mol Pharmacol (1999) 0.94
The conformation of cyclo(-D-Pro-Ala4-) as a model for cyclic pentapeptides of the DL4 type. J Am Chem Soc (2006) 0.92
Solid-phase, Pd-catalyzed silicon-aryl carbon bond formation. Synthesis of sansalvamide A peptide. Org Lett (2002) 0.92
Scaffold targeting drug-resistant colon cancers. J Med Chem (2007) 0.91
Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. Bioorg Med Chem Lett (2007) 0.91
Synthesis and novel structure-activity relationships of potent sansalvamide A derivatives. Chem Commun (Camb) (2006) 0.90
Modeling of peptides containing D-amino acids: implications on cyclization. J Comput Aided Mol Des (2009) 0.89
Synthesis and cytotoxicity of novel sansalvamide A derivatives. Org Lett (2005) 0.89
Heat shock proteins are differentially expressed in human gastrointestinal cancers. Surg Oncol (1995) 0.88
Rapid, high-yield, solid-phase synthesis of the antitumor antibiotic sansalvamide A using a side-chain-tethered phenylalanine building block. Org Lett (2000) 0.84
Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des (2007) 0.84
Macrocyclic inhibitors of hsp90. Curr Top Med Chem (2010) 0.83
Multiple solution conformations of the integrin-binding cyclic pentapeptide cyclo(-Ser-D-Leu-Asp-Val-Pro-). Analysis of the (phi, psi) space available to cyclic pentapeptides. Eur J Biochem (1996) 0.82
Transactivation of hsp70-1/2 in geldanamycin-treated human non-small cell lung cancer H460 cells: involvement of intracellular calcium and protein kinase C. J Cell Biochem (2005) 0.81
Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect. Int J Biochem Cell Biol (2006) 0.79
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 2.81
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther (2002) 2.07
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis (2008) 1.91
The Drosophila takeout gene is regulated by the somatic sex-determination pathway and affects male courtship behavior. Genes Dev (2002) 1.82
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
A versatile in vivo system for directed dissection of gene expression patterns. Nat Methods (2011) 1.64
A blended learning experience for teaching microbiology. Am J Pharm Educ (2006) 1.56
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med (2015) 1.47
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Synthesis of second-generation sansalvamide A derivatives: novel templates as potential antitumor agents. J Org Chem (2007) 1.26
Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines. J Med Chem (2008) 1.17
Phosphatidic acid and N-acylphosphatidylethanolamine form membrane domains in Escherichia coli mutant lacking cardiolipin and phosphatidylglycerol. J Biol Chem (2008) 1.12
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS (2008) 1.05
A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorg Med Chem (2009) 1.04
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics (2006) 1.03
Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. ACS Med Chem Lett (2010) 1.02
Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90. Bioorg Med Chem Lett (2011) 1.01
Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr (2004) 1.00
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
Simplification of the Mitsunobu reaction. Di-p-chlorobenzyl azodicarboxylate: a new azodicarboxylate. Org Lett (2006) 0.99
Synthesis of Sansalvamide A derivatives and their cytotoxicity in the MSS colon cancer cell line HT-29. Bioorg Med Chem (2006) 0.97
Bioconjugation by native chemical tagging of C-H bonds. J Am Chem Soc (2013) 0.95
A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents. Chem Biol (2004) 0.94
Farnesol-detecting olfactory neurons in Drosophila. J Neurosci (2014) 0.94
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med (2009) 0.93
Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chem Biol (2011) 0.93
Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr (2010) 0.92
C-H methylation of heteroarenes inspired by radical SAM methyl transferase. J Am Chem Soc (2014) 0.92
Scaffold targeting drug-resistant colon cancers. J Med Chem (2007) 0.91
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther (2007) 0.91
Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds. Tetrahedron (2012) 0.91
Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. Bioorg Med Chem Lett (2007) 0.91
Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett (2013) 0.91
Synthesis and novel structure-activity relationships of potent sansalvamide A derivatives. Chem Commun (Camb) (2006) 0.90
Synthesis and cytotoxicity of novel sansalvamide A derivatives. Org Lett (2005) 0.89
Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles. Org Lett (2007) 0.89
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr (2004) 0.89
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials (2015) 0.89
Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett (2012) 0.88
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol (2002) 0.87
Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. J Control Release (2005) 0.87
Conformationally based design of macrocycles as antitumor agents. Curr Opin Drug Discov Devel (2008) 0.87
Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J (2010) 0.87
A new and improved method for deglycosidation of glycopeptide antibiotics exemplified with vancomycin, ristocetin, and ramoplanin. Bioorg Med Chem Lett (2003) 0.86
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr (2009) 0.85
Palau'chlor: a practical and reactive chlorinating reagent. J Am Chem Soc (2014) 0.85
Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold. Bioorg Med Chem Lett (2008) 0.84
Influence of graphene oxide on metal-insulator-semiconductor tunneling diodes. Nanoscale Res Lett (2012) 0.84
Increased Risk of Restless Legs Syndrome in Patients With Migraine: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2016) 0.83
Macrocyclic inhibitors of hsp90. Curr Top Med Chem (2010) 0.83
Novel antibiotics: C-2 symmetrical macrocycles inhibiting Holliday junction DNA binding by E. coli RuvC. Bioorg Med Chem (2006) 0.83
Disaster preparedness for children and families: a critical review. Curr Psychiatry Rep (2015) 0.82
Novel antibiotics: macrocyclic peptides designed to trap Holliday junctions. Org Lett (2003) 0.81
Progress towards the synthesis of Urukthapelstatin A and two analogues. Tetrahedron Lett (2012) 0.81
Apolipoprotein E modifies the CNS response to injury via a histamine-mediated pathway. Neurol Res (2007) 0.81
Risk of Restless Legs Syndrome Following Tension-Type Headache: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.80
Reversal of ophthalmic artery flow and stroke outcomes in Asian patients with acute ischemic stroke and unilateral severe cervical carotid stenosis. PLoS One (2013) 0.80
An Hsp90 modulator that exhibits a unique mechanistic profile. Bioorg Med Chem Lett (2012) 0.80
Lymphocytic host response to oral squamous cell carcinoma: an adaptive T-cell response at the tumor interface. Head Neck Pathol (2011) 0.80
Risk of vancomycin-induced nephrotoxicity in the population with chronic kidney disease. Am J Med Sci (2013) 0.80
A small molecule that preferentially binds the closed conformation of Hsp90. Bioorg Med Chem Lett (2011) 0.79
Total synthesis of trans,trans-Sanguinamide B and conformational isomers. Org Lett (2012) 0.79
ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther (2012) 0.79
A structure-activity relationship study on multi-heterocyclic molecules: two linked thiazoles are required for cytotoxic activity. Medchemcomm (2012) 0.79
Synthesis, structure-activity analysis, and biological evaluation of sanguinamide B analogues. J Org Chem (2012) 0.79
Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan. Ann Vasc Surg (2010) 0.78
The effects of a support group on dementia caregivers' burden and depression. J Aging Health (2010) 0.78